MX2020004883A - Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. - Google Patents
Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales.Info
- Publication number
- MX2020004883A MX2020004883A MX2020004883A MX2020004883A MX2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A MX 2020004883 A MX2020004883 A MX 2020004883A
- Authority
- MX
- Mexico
- Prior art keywords
- exosomes
- methods
- payloads
- luminal
- loading
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Botany (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención se refiere a métodos para preparar un exosoma terapéutico usando proteínas recientemente identificadas para ser enriquecidas en el lumen de exosomas. Específicamente, la presente invención proporciona métodos para localizar una proteína o péptido terapéutico en exosomas. Los métodos implican la generación de exosomas modificados en el lumen que incluyen una o más de las proteínas de exosoma a concentraciones mayores, una modificación o un fragmento de la proteína de exosoma, o una proteína de fusión de la proteína de exosoma y una proteína terapéutica o de carga.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762587767P | 2017-11-17 | 2017-11-17 | |
US201862634750P | 2018-02-23 | 2018-02-23 | |
PCT/US2018/061679 WO2019099942A1 (en) | 2017-11-17 | 2018-11-16 | Compositions of engineered exosomes and methods of loading luminal exosomes payloads |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004883A true MX2020004883A (es) | 2020-08-06 |
Family
ID=66534134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004883A MX2020004883A (es) | 2017-11-17 | 2018-11-16 | Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. |
Country Status (11)
Country | Link |
---|---|
US (3) | US20200347112A1 (es) |
JP (2) | JP2021503300A (es) |
KR (1) | KR20200091390A (es) |
CN (1) | CN111511384A (es) |
AR (1) | AR115159A1 (es) |
AU (1) | AU2018367670A1 (es) |
CA (2) | CA3234784A1 (es) |
IL (1) | IL274634A (es) |
MX (1) | MX2020004883A (es) |
SG (1) | SG11202003871SA (es) |
WO (1) | WO2019099942A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019246591A1 (en) | 2018-06-21 | 2019-12-26 | Codiak Biosciences, Inc. | Methods of measuring extracellular vesicles and nanoparticles in complex matrices by light scattering |
PT3672614T (pt) * | 2018-11-16 | 2022-02-11 | Codiak Biosciences Inc | Vesículas extracelulares modificadas e suas utilizações |
CA3128386A1 (en) * | 2019-02-04 | 2020-08-13 | Codiak Biosciences, Inc. | Membrane protein scaffolds for exosome engineering |
KR20220009389A (ko) * | 2019-04-17 | 2022-01-24 | 코디악 바이오사이언시즈, 인크. | 엑소좀 및 aav 의 조성물 |
US20240024220A1 (en) * | 2019-05-11 | 2024-01-25 | Youngsuk Yi | Neurotoxin compositions and methods |
WO2021003445A1 (en) | 2019-07-03 | 2021-01-07 | Codiak Biosciences, Inc. | Extracellular vesicles targeting t cells and uses thereof |
JP2022544288A (ja) | 2019-08-14 | 2022-10-17 | コディアック バイオサイエンシーズ, インコーポレイテッド | CEBP/βを標的とする細胞外小胞-ASO構築物 |
WO2021030768A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with stat3-antisense oligonucleotides |
CN114829586A (zh) | 2019-08-14 | 2022-07-29 | 科迪亚克生物科学公司 | 细胞外囊泡-nlrp3拮抗剂 |
BR112022002691A2 (pt) | 2019-08-14 | 2022-08-23 | Codiak Biosciences Inc | Construtos de vesícula-aso extracelular visando stat6 |
CA3147701A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
WO2021062060A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes combined with il-12 displaying exosomes for treating a tumour |
US20230103726A1 (en) | 2019-09-25 | 2023-04-06 | Codiak Biosciences, Inc. | Methods of producing extracellular vesicles |
WO2021062057A1 (en) | 2019-09-25 | 2021-04-01 | Codiak Biosciences, Inc. | Exogenous loading of exosomes via lyophilization |
EP4034247A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
EP4034081A1 (en) | 2019-09-25 | 2022-08-03 | Codiak BioSciences, Inc. | Extracellular vesicle compositions |
WO2021092193A1 (en) | 2019-11-05 | 2021-05-14 | Codiak Biosciences, Inc. | High-throughput chromatography screening for extracellular vesicles |
WO2021146616A1 (en) | 2020-01-17 | 2021-07-22 | Codiak Biosciences, Inc. | Cholesterol assays for quantifying extracellular vesicles |
EP4097474A4 (en) * | 2020-01-27 | 2024-03-27 | Mantra Bio Inc | NON-NATURALLY OCCURRING VESICLES COMPRISING A CHIMERIC VESICLE LOCALIZATION COMPONENT, METHODS OF PREPARATION AND USES THEREOF |
EP4099984A4 (en) | 2020-02-05 | 2024-05-01 | Diadem Biotherapeutics Inc | ARTIFICIAL SYNAPSES |
WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
EP4117717A1 (en) | 2020-03-13 | 2023-01-18 | Codiak BioSciences, Inc. | Extracellular vesicles for treating neurological disorders |
WO2021189047A2 (en) | 2020-03-20 | 2021-09-23 | Codiak Biosciences, Inc. | Extracellular vesicles for therapy |
WO2021228832A1 (en) | 2020-05-11 | 2021-11-18 | Erytech Pharma | Red cell extracellular vesicles (rcevs) containing cargoes and methods of use and production thereof |
US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
AU2021320419A1 (en) * | 2020-08-07 | 2023-03-09 | Amicus Therapeutics, Inc. | Vesicle targeting proteins and uses of same |
JP2023538077A (ja) | 2020-08-17 | 2023-09-06 | コディアック バイオサイエンシーズ, インコーポレイテッド | がんの治療方法 |
CA3193107A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
WO2022066883A1 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Extracellular vesicles comprising kras antigens and uses thereof |
WO2022066928A2 (en) | 2020-09-23 | 2022-03-31 | Codiak Biosciences, Inc. | Process for preparing extracellular vesicles |
US20240082389A1 (en) | 2020-09-23 | 2024-03-14 | Lonza Sales Ag | Methods of producing extracellular vesicles |
WO2022076596A1 (en) | 2020-10-06 | 2022-04-14 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
CN112410304A (zh) * | 2020-11-12 | 2021-02-26 | 天津大学 | 一种基因修饰的外泌体及其制备方法和应用 |
CN112903999A (zh) * | 2021-01-20 | 2021-06-04 | 蚌埠医学院第一附属医院(蚌埠医学院附属肿瘤医院) | 一种用于纳米流式细胞仪检测的外泌体的制备方法及应用 |
IL305171A (en) | 2021-02-17 | 2023-10-01 | Lonza Sales Ag | EXTRACELLULAR VESILE-NLRP3 antagonist |
KR20230157346A (ko) * | 2021-02-17 | 2023-11-16 | 론자 세일즈 아게 | 세포외 소포체를 로딩하는 방법 |
CN117120041A (zh) | 2021-04-01 | 2023-11-24 | 隆萨销售股份有限公司 | 胞外囊泡组合物 |
WO2023027082A1 (ja) * | 2021-08-23 | 2023-03-02 | 積水化学工業株式会社 | ペプチド結合ハイブリッドリポソームエクソソーム、ペプチド結合エクソソーム、これらを含む組成物及びその形成方法 |
WO2023064924A1 (en) | 2021-10-14 | 2023-04-20 | Codiak Biosciences, Inc. | Modified producer cells for extracellular vesicle production |
WO2023085821A1 (ko) * | 2021-11-10 | 2023-05-19 | 주식회사 씨케이엑소젠 | 엑소좀 기반 항바이러스 백신 및 이의 제조방법 |
WO2023091905A1 (en) * | 2021-11-19 | 2023-05-25 | Elmaleh David R | Targeted extracellular vesicles and methods of use thereof |
WO2023183794A2 (en) * | 2022-03-24 | 2023-09-28 | Mercury Bio, Inc. | Direct production of sirnas in saccharomyces boulardii and packaging in extracellular vesicles (evs) for targeted gene silencing |
CN117126886A (zh) * | 2022-05-20 | 2023-11-28 | 谛邈生物科技(北京)有限公司 | 一种实现工程化EVs功能蛋白模块化装载的核酸构建体及其应用 |
CN116656705A (zh) * | 2023-04-18 | 2023-08-29 | 河南中医药大学第一附属医院 | pHLIP-Lamp2b-1/2融合蛋白重组质粒及其构建、应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1412498A2 (en) * | 2001-07-17 | 2004-04-28 | Novartis AG | Polynucleotides expressed in dendritic cells and polypeptides encoded thereby |
EP3569254B1 (en) * | 2009-04-17 | 2022-07-20 | Oxford University Innovation Limited | Composition for delivery of genetic material |
CN103002879B (zh) * | 2010-07-01 | 2016-04-20 | 阿昂梅迪克斯公司 | 来自细胞原生质体的微泡及其应用 |
GB201121069D0 (en) * | 2011-12-07 | 2012-01-18 | Isis Innovation | Delivery system |
WO2016172598A1 (en) * | 2015-04-22 | 2016-10-27 | The Broad Institute Inc. | Exosomes and uses thereof |
US10624849B2 (en) * | 2015-09-28 | 2020-04-21 | Northwestern University | Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites |
WO2017117585A1 (en) * | 2015-12-30 | 2017-07-06 | The Regents Of The University Of California | Methods for enhanced production and isolation of cell-derived vesicles |
WO2017147719A1 (en) * | 2016-03-04 | 2017-09-08 | Exerkine Corporation | Method for treating neuropathy |
-
2018
- 2018-11-16 US US16/765,116 patent/US20200347112A1/en not_active Abandoned
- 2018-11-16 WO PCT/US2018/061679 patent/WO2019099942A1/en active Application Filing
- 2018-11-16 SG SG11202003871SA patent/SG11202003871SA/en unknown
- 2018-11-16 MX MX2020004883A patent/MX2020004883A/es unknown
- 2018-11-16 CN CN201880072250.2A patent/CN111511384A/zh active Pending
- 2018-11-16 CA CA3234784A patent/CA3234784A1/en active Pending
- 2018-11-16 AU AU2018367670A patent/AU2018367670A1/en active Pending
- 2018-11-16 US US16/194,230 patent/US20190151456A1/en not_active Abandoned
- 2018-11-16 JP JP2020545049A patent/JP2021503300A/ja active Pending
- 2018-11-16 KR KR1020207011470A patent/KR20200091390A/ko not_active Application Discontinuation
- 2018-11-16 CA CA3082588A patent/CA3082588A1/en active Pending
-
2019
- 2019-05-23 AR ARP190101375A patent/AR115159A1/es unknown
-
2020
- 2020-05-13 IL IL274634A patent/IL274634A/en unknown
-
2022
- 2022-11-21 US US18/057,709 patent/US20240000944A1/en active Pending
-
2023
- 2023-11-28 JP JP2023200466A patent/JP2024015074A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2021503300A (ja) | 2021-02-12 |
JP2024015074A (ja) | 2024-02-01 |
AU2018367670A1 (en) | 2020-05-07 |
US20240000944A1 (en) | 2024-01-04 |
KR20200091390A (ko) | 2020-07-30 |
WO2019099942A1 (en) | 2019-05-23 |
US20190151456A1 (en) | 2019-05-23 |
CA3234784A1 (en) | 2019-05-23 |
CN111511384A (zh) | 2020-08-07 |
AR115159A1 (es) | 2020-12-02 |
SG11202003871SA (en) | 2020-05-28 |
IL274634A (en) | 2020-06-30 |
US20200347112A1 (en) | 2020-11-05 |
CA3082588A1 (en) | 2019-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004883A (es) | Composiciones de exosomas modificados y metodos de cargar cargas de exosomas luminales. | |
CL2021001278A1 (es) | Vesículas extracelulares modificadas y sus usos | |
CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
CO2017001023A2 (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
CL2019002534A1 (es) | Plataforma de identificación de peptidos inmunogénicos personalizados. | |
CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
CL2017000311A1 (es) | Anticuerpos anti-lag3 y fragmentos de unión a antígeno | |
ECSP17048849A (es) | Terapias de combinación para el tratamiento de cánceres | |
ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
CL2022003377A1 (es) | Péptidos y combinaciones para uso en inmunoterapia contra el cáncer de páncreas y otros cánceres (solicitud divisional 201703235) | |
CY1123963T1 (el) | Καινοτομα πολυμερικα προφαρμακα hgh | |
MX2018011491A (es) | Disposiciones de secuencia y secuencias para presentacion de neoepitopos. | |
CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
SV2018005714A (es) | Composiciones y metodos para disminuir la expresion de tau | |
AR095334A1 (es) | Composiciones nutricionales que contienen un componente peptídico con propiedades estimulantes de la adiponectina y método para promover un peso corporal saludable | |
CL2020003447A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas | |
UY36173A (es) | Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia | |
CL2015001446A1 (es) | Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido. | |
CL2023000892A1 (es) | Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional). | |
CL2020001781A1 (es) | Un péptido de nudo de cistina (ckp) de origen no natural que se une a la proteína relacionada con el receptor de lipoproteína de baja densidad 6 (lrp6) humana. (divisional solicitud 201800668) | |
PE20190966A1 (es) | Factor viii direccionado a los globulos rojos y metodo para su uso | |
CO2021003136A2 (es) | Terapias de combinación |